Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With Atorvastatin in Patients With Primary Hypercholesterolemia and LDL-cholesterol ≥ 100 mg/dL

This study has been completed.
Sponsor:
Collaborator:
Regeneron Pharmaceuticals
Information provided by (Responsible Party):
Sanofi
ClinicalTrials.gov Identifier:
NCT01288469
First received: February 1, 2011
Last updated: January 23, 2015
Last verified: January 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2011
  Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: December 12, 2012